Case studies

octenidine in the management of diabetic foot ulcers

Andrew Sharpe, Ana Formiga, Jose Neves, Eugenia Serafino, Claudia Silva, Marino Machado

Research output: Contribution to journalArticle

23 Downloads (Pure)

Abstract

Diabetic foot ulcers (DFUs) are common and constitute a considerable burden
for both patients and healthcare providers. Reducing the length of time to
healing reduces the risk of infection and further morbidity. Biofilms delay
healing, therefore, they should be treated with a biofilm-based wound care
regimen consisting of debridement, topical agents (antimicrobials and antiseptics)
and, if appropriate, systemic antibiotics (Cutting and Westgate, 2012). This
case series focuses on the use of octenilin®, which contains a broad-spectrum
antimicrobial, in the treatment of DFUs to address bioburden, prevent infection
and progress healing.
Original languageEnglish
Pages (from-to)192-197
Number of pages6
JournalThe Diabetic Foot Journal
Volume21
Issue number3
Publication statusPublished - 13 Sep 2018

Fingerprint

octenidine
Diabetic Foot
Biofilms
Local Anti-Infective Agents
Debridement
Anti-Infective Agents
Health Personnel
Anti-Bacterial Agents
Morbidity
Wounds and Injuries
Infection
Therapeutics

Cite this

Sharpe, A., Formiga, A., Neves, J., Serafino, E., Silva, C., & Machado, M. (2018). Case studies: octenidine in the management of diabetic foot ulcers. The Diabetic Foot Journal, 21(3), 192-197.
Sharpe, Andrew ; Formiga, Ana ; Neves, Jose ; Serafino, Eugenia ; Silva, Claudia ; Machado, Marino. / Case studies : octenidine in the management of diabetic foot ulcers. In: The Diabetic Foot Journal. 2018 ; Vol. 21, No. 3. pp. 192-197.
@article{68f14cc7947949fca5184a0e2d52b0f7,
title = "Case studies: octenidine in the management of diabetic foot ulcers",
abstract = "Diabetic foot ulcers (DFUs) are common and constitute a considerable burdenfor both patients and healthcare providers. Reducing the length of time tohealing reduces the risk of infection and further morbidity. Biofilms delayhealing, therefore, they should be treated with a biofilm-based wound careregimen consisting of debridement, topical agents (antimicrobials and antiseptics)and, if appropriate, systemic antibiotics (Cutting and Westgate, 2012). Thiscase series focuses on the use of octenilin{\circledR}, which contains a broad-spectrumantimicrobial, in the treatment of DFUs to address bioburden, prevent infectionand progress healing.",
keywords = "Biofilm, Diabetic foot ulcer",
author = "Andrew Sharpe and Ana Formiga and Jose Neves and Eugenia Serafino and Claudia Silva and Marino Machado",
year = "2018",
month = "9",
day = "13",
language = "English",
volume = "21",
pages = "192--197",
journal = "The Diabetic Foot Journal",
issn = "1462-2041",
number = "3",

}

Sharpe, A, Formiga, A, Neves, J, Serafino, E, Silva, C & Machado, M 2018, 'Case studies: octenidine in the management of diabetic foot ulcers', The Diabetic Foot Journal, vol. 21, no. 3, pp. 192-197.

Case studies : octenidine in the management of diabetic foot ulcers. / Sharpe, Andrew; Formiga, Ana; Neves, Jose; Serafino, Eugenia; Silva, Claudia; Machado, Marino.

In: The Diabetic Foot Journal, Vol. 21, No. 3, 13.09.2018, p. 192-197.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Case studies

T2 - octenidine in the management of diabetic foot ulcers

AU - Sharpe, Andrew

AU - Formiga, Ana

AU - Neves, Jose

AU - Serafino, Eugenia

AU - Silva, Claudia

AU - Machado, Marino

PY - 2018/9/13

Y1 - 2018/9/13

N2 - Diabetic foot ulcers (DFUs) are common and constitute a considerable burdenfor both patients and healthcare providers. Reducing the length of time tohealing reduces the risk of infection and further morbidity. Biofilms delayhealing, therefore, they should be treated with a biofilm-based wound careregimen consisting of debridement, topical agents (antimicrobials and antiseptics)and, if appropriate, systemic antibiotics (Cutting and Westgate, 2012). Thiscase series focuses on the use of octenilin®, which contains a broad-spectrumantimicrobial, in the treatment of DFUs to address bioburden, prevent infectionand progress healing.

AB - Diabetic foot ulcers (DFUs) are common and constitute a considerable burdenfor both patients and healthcare providers. Reducing the length of time tohealing reduces the risk of infection and further morbidity. Biofilms delayhealing, therefore, they should be treated with a biofilm-based wound careregimen consisting of debridement, topical agents (antimicrobials and antiseptics)and, if appropriate, systemic antibiotics (Cutting and Westgate, 2012). Thiscase series focuses on the use of octenilin®, which contains a broad-spectrumantimicrobial, in the treatment of DFUs to address bioburden, prevent infectionand progress healing.

KW - Biofilm

KW - Diabetic foot ulcer

M3 - Article

VL - 21

SP - 192

EP - 197

JO - The Diabetic Foot Journal

JF - The Diabetic Foot Journal

SN - 1462-2041

IS - 3

ER -

Sharpe A, Formiga A, Neves J, Serafino E, Silva C, Machado M. Case studies: octenidine in the management of diabetic foot ulcers. The Diabetic Foot Journal. 2018 Sep 13;21(3):192-197.